Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.

Autor: Brieva L; Hospital Arnau de Vilanova, IRBLLEIDA, Lleida, Spain., Estruch BC; Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Merino JAG; Fundación de Investigación Puerta de Hierro, Universidad Autónoma de Madrid, Spain., Meca-Lallana V; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario 'La Princesa', Madrid, Spain., Río J; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Rodríguez-Antigüedad A; Neuroimmunology and Multiple Sclerosis Unit, Hospital Universitario de Cruces, Barakaldo, Spain., Agüera E; Neurología, Hospital Universitario Reina Sofía - IMIBIC, Córdoba, Spain., Ara JR; Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain., Luque AA; Neurología, Complejo Asistencial Universitario de León, Spain., Garcia CA; Hospital Virgen de las Nieves, Granada, Spain., Blanco Y; Unidad de Neuroimmunología y Esclerosis múltiple, Hospital Clínic, Barcelona, Spain., Castillo-Triviño T; Biodonostia Health Research Institute, Neurosciences Area, Multiple Sclerosis Group, Basque Health Service, Neurology Department, San Sebastian, Spain., Costa-Frossard L; CSUR de Esclerosis Múltiple, Servicio de Neurología, Fundación para la Investigación Biomédica IRyCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain., González Platas M; Servicio de Neurología, Hospital Universitario de Canarias, Tenerife, España, Spain., Pascual LL; Servicio de Neurología, Hospital Universitario Dr Peset, Valencia, Spain., Llaneza-González M; Servicio de Neurología, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain., Ginés MLM; Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Matías-Guiu J; Department of Neurology, Hospital Clínico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, Madrid, Spain., Meca-Lallana JE; CSUR Multiple Sclerosis and Clinical Neuroimmunology Unit, Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain., Bilbao MM; Neuroimmunology and Multiple Sclerosis Unit, Hospital Universitario de Cruces, Barakaldo, Spain., Sempere AP; Neurology Service, Hospital General Universitario de Alicante, Alicante 03010, Spain., Romero-Pinel L; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge (IDIBELL), L'Hospitalet de LLobregat, Barcelona, Spain., Saiz A; Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain., Moral E; Servicio de Neurología, Hospital Moises Broggi, Sant Joan Despí, Barcelona, Spain; Servicio de Neurología, Hospital General de L'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain. Electronic address: ester.moral@sanitatintegral.org.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2022 Jul; Vol. 63, pp. 103805. Date of Electronic Publication: 2022 Apr 12.
DOI: 10.1016/j.msard.2022.103805
Abstrakt: Background: The increase in available disease modifying therapies (DMTs) for multiple sclerosis has led to greater emphasis on improving treatment sequencing paradigms. This article summarises the opinions from a panel of 25 experts on treatment switching approaches in relapsing multiple sclerosis (RMS).
Methods: A modified Delphi consensus process was carried out to develop clinically relevant statements for aiding treatment decisions in patients with RMS between the 16 th January and the 9 th October 2019. A sub-group of two experts (core group) carried out an extensive review of the literature and formulated 106 statements for the expert panel to evaluate.
Results: From a total number of 106 statements that were submitted to the expert panel for critical evaluation, consensus (at least 80% of the panelists agreed) was reached on 99 of them. These statements cover treatment objectives, reasons for DMT switching, suboptimal response criteria, strategies for treatment change and washout periods.
Conclusion: The agreed statements provide up-to-date guidance on DMT sequencing for optimal patient management.
(Copyright © 2022. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: